中国实用妇科与产科杂志

中国实用妇科与产科杂志

• 专题笔谈 • 上一篇    下一篇

局部晚期宫颈癌靶向治疗的现状和未来

  

  1. 1.首都医科大学附属北京朝阳医院妇产科，北京 100069；2.广东医科大学附属医院肿瘤科，广东 湛江 524000
  • 出版日期:2018-11-02 发布日期:2018-11-06
  • 通讯作者: 张震宇
  • 基金资助:

    北京市医院管理局临床医学发展专项经费资助扬帆计划（ZYLX201713）

Current status and future of targeted therapy for patients with local advanced cervical cancer.

  1. Capital Medical University，Beijing Chaoyang Hospital，Department of Obstetrics and Gynecology，Beijing 100069，China
  • Online:2018-11-02 Published:2018-11-06

摘要：

近年来，由于宫颈癌筛查的普及，全球宫颈癌发病率呈现下降趋势，约80%以上宫颈癌患者发生在发展中国家，而且年轻妇女宫颈癌的发生率在逐渐上升。对于晚期宫颈癌患者，虽然放疗和化疗有一定的疗效，但是中位生存时间也仅1年。靶向治疗在治疗晚期肿瘤方面取得了巨大的成就，临床研究已经证实贝伐单抗联合化疗可有效延长晚期宫颈癌患者的总生存时间，而且越来越多的靶向药物也被用于研究对晚期宫颈癌的治疗上。

关键词: 宫颈肿瘤, 局部晚期, 靶向治疗, 表皮生长因子受体, 血管内皮生长因子

Abstract:

In recent years，with the popularization of cervical cancer screening，the global incidence of cervical cancer is declining gradually.However，more than 80% of cervical cancer occurs in developing countries，and the incidence rate of cervical cancer in young women is rising.For patients with advanced cervical cancer，radiotherapy and chemotherapy have a moderate effect，but the median survival time is just one year.Targeted therapy makes great achievement in advanced cancer treatment.Clinical trials suggest that bevacizumab combined with chemotherapy effectively prolongs the overall survival time of patients with cervical cancer.On the other side，more and more targeted drugs are being used in the treatment of advanced cervical cancer.

Key words: cervical neoplasm, locally advanced, targeted therapy, EGFR, VEGF

中图分类号: